Clinical trial · no report yet · Phase 2
ELM-2
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
- NCT03888105 ↗
- Active not recruiting
- Regeneron Pharmaceuticals
- 36 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 16 | |
| YouTube | 12 | |
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- Interventions
- Odronextamab
- Arms
- FL · Experimental
- DLBCL · Experimental
- MCL · Experimental
- MZL · Experimental
- Other B-NHL · Experimental
- Enrollment
- 515
- Primary outcomes
- Objective Response Rate (ORR), as assessed by independent central review
- ORR, as assessed by independent central review
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 13, 2019
- Primary completion
- Jun 17, 2026
- Results posted
- No
- Registry record
- NCT03888105 · updated Jul 31, 2026
Publications
linked from the registry- Villasboas JC, Poon M, Tani M, Jimenez-Ubieto A, Tessoulin B, Warwick L, Brown D, Namuduri M, Lin C, Delwart V, Jagadeesh D. Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study. Future Oncol. 2026 Mar;22(6):643-658. doi: 10.1080/14796694.2026.2628111. Epub 2026 Mar 1. PubMed 41766170
- Arnason JE, Matasar M, Luminari S, Tucker D, Sun D, Tao W, Zhu YO, Kundu K, Gupta NT, Leary A, Jankovic V, Ambati S, Mohamed H, Chaudhry A, Brouwer-Visser J. Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. Blood Adv. 2025 Dec 9;9(23):6130-6140. doi: 10.1182/bloodadvances.2025016332. PubMed 40902079
- Danilov AV, Kambhampati Thiruvengadam S, Linton K, Cumings K, Chirikov V, Mutebi A, Bains Chawla S, Chhibber A, Rivas Navarro F, Marques Goncalves F, Wang A, Ding Z, Alshreef A, Favaro E, Hoehn D, Sureda A. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood Adv. 2025 Aug 12;9(15):3754-3765. doi: 10.1182/bloodadvances.2024015274. PubMed 40472301
- Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jazdzewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17. PubMed 40097657